文献速递前列腺癌

术前PSMA PET/CT高SUVmax与机器人辅助根治性前列腺切除术后转移风险相关

Higher Preoperative Maximum Standardised Uptake Values Are Associated with a Higher Risk of Metastases After Robot-assisted Radical Prostatectomy for Patients Undergoing 68Ga-PSMA-11 and 18F-DCFPyL Positron Emission Tomography/Computed Tomography.
PubMed 文献 · Eur Urol Oncol · 2025-12-18

这项回顾性双中心研究纳入293例非转移性前列腺癌患者,术前接受68Ga-PSMA-11或18F-DCFPyL PSMA PET/CT,评估SUVmax对机器人辅助根治性前列腺切除术后转移的预测价值。中位随访39个月,53例发生转移;转移者SUVmax更高(中位8.8 vs 7.8,P=0.015)。SUVmax>10与转移风险增加相关(HR 1.81,95%CI 1.04-3.13,P=0.035),log-SUVmax独立预测转移(HR 2.80,95%CI 1.02-7.70,P=0.046)。

要点

  • 术前PSMA PET/CT SUVmax>10与RARP术后转移风险增加相关。
  • 转移患者术前SUVmax中位8.8,无转移者7.8,差异有统计学意义。
  • log-SUVmax是RARP术后转移的独立预测因素。

核心结论

  • 在原发性前列腺癌患者中,术前PSMA PET/CT SUVmax与RARP术后转移进展相关。
  • SUVmax>10可能有助于对不良结局进行风险分层。

研究设计与样本

  • 回顾性双中心研究,纳入293例非转移性原发性前列腺癌患者。
  • 患者术前接受[68Ga]Ga-PSMA-11或[18F]DCFPyL PSMA PET/CT,随后行RARP,最低随访1年。
  • 转移通过生化复发时的再分期PSMA PET/CT评估。
  • SUVmax取术前PSMA PET/CT上优势前列腺内病灶的数值。
  • 多变量Cox回归纳入SUVmax、临床T分期、初始PSA密度、活检阳性针数百分比和活检ISUP分级分组。

主要发现

  • 中位随访39个月(IQR 29-54),53例发生转移。
  • 转移者2年随访时SUVmax中位8.8(IQR 7.1-16),无转移者7.8(IQR 5.7-13),p=0.015。
  • SUVmax>10与转移风险增加相关(HR 1.81;95%CI 1.04-3.13;p=0.035)。
  • log-SUVmax独立预测转移(HR 2.80;95%CI 1.02-7.70;p=0.046)。

关键数值与推荐

  • SUVmax>10与转移风险增加相关(HR 1.81;95%CI 1.04-3.13;p=0.035)。
  • log-SUVmax独立预测转移(HR 2.80;95%CI 1.02-7.70;p=0.046)。
  • 转移者SUVmax中位8.8(IQR 7.1-16),无转移者7.8(IQR 5.7-13),p=0.015。

临床怎么用

  • 术前PSMA PET/CT SUVmax可作为RARP术后转移风险分层的参考指标。
  • SUVmax>10提示转移风险增高,可能需更密切的术后随访。

局限性

  • 选择性随访影像和非标准化治疗决策可能导致选择偏倚和检测偏倚。
  • 回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) expression on positron emission tomography/computed tomography (PET/CT), semiquantitatively expressed as the standardised uptake value (SUVmax), is increasingly recognised as a prognostic factor and may predict metastatic progression after treatment. This study aims to evaluate the predictive value of SUVmax on preoperative PSMA PET/CT for metastatic development after robot-assisted radical prostatectomy (RARP). METHODS: This retrospective two-centre study included patients with nonmetastatic primary prostate cancer who underwent [68Ga]Ga-PSMA-11 or [18F]DCFPyL PSMA PET/CT prior to RARP. The minimum follow-up period was 1 yr. Metastases were assessed by restaging PSMA PET/CT at biochemical recurrence. SUVmax was calculated for the dominant intraprostatic lesion on preoperative PSMA PET/CT. Multivariable Cox regression included SUVmax, clinical tumour stage (cT), initial prostate-specific antigen density, percentage positive biopsy cores, and biopsy International Society of Urological Pathology grade group. SUVmax thresholds and model performance were investigated. KEY FINDINGS AND LIMITATIONS: A total of 293 patients underwent preoperative PSMA PET/CT, of whom 53 developed metastases after a median follow-up of 39 mo (interquartile range [IQR] 29-54). SUVmax was higher in participants who developed metastases at 2-yr follow-up than in those without metastases (median 8.8; IQR 7.1-16 vs 7.8; IQR 5.7-13; p = 0.015). An SUVmax of >10 was associated with an increased metastatic risk (hazard ratio [HR] 1.81; 95% confidence interval [CI] 1.04-3.13; p = 0.035) and log-SUVmax independently predicted metastases (HR 2.80; 95% CI 1.02-7.70; p = 0.046). The limitations include potential selection and detection biases due to selective follow-up imaging and nonstandardised treatment decisions. CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with primary prostate cancer, preoperative SUVmax is associated with metastatic progression after RARP. An SUVmax of >10 may aid in risk stratification for adverse outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. de Bie KCC, Creanza MF, Bodar YJL, et al. Higher Preoperative Maximum Standardised Uptake Values Are Associated with a Higher Risk of Metastases After Robot-assisted Radical Prostatectomy for Patients Undergoing 68Ga-PSMA-11 and 18F-DCFPyL Positron Emission Tomography/Computed Tomography. Eur Urol Oncol. 2025. PMID: 41419412. doi:10.1016/j.euo.2025.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。